SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,502 | -66.0% | 12,510 | -25.1% | 0.00% | – |
| Q2 2023 | $22,090 | -32.7% | 16,700 | -13.1% | 0.00% | – |
| Q1 2023 | $32,805 | -45.7% | 19,223 | +1.8% | 0.00% | – |
| Q4 2022 | $60,413 | -42.5% | 18,892 | -11.5% | 0.00% | – |
| Q3 2022 | $105,000 | +18.0% | 21,350 | 0.0% | 0.00% | – |
| Q2 2022 | $89,000 | -53.6% | 21,350 | -10.7% | 0.00% | – |
| Q1 2022 | $192,000 | +20.0% | 23,897 | +12.7% | 0.00% | – |
| Q4 2021 | $160,000 | -19.6% | 21,213 | -3.5% | 0.00% | – |
| Q3 2021 | $199,000 | -18.4% | 21,976 | +8.2% | 0.00% | -100.0% |
| Q2 2021 | $244,000 | -30.9% | 20,312 | -28.0% | 0.00% | 0.0% |
| Q1 2021 | $353,000 | +37.4% | 28,192 | +69.6% | 0.00% | 0.0% |
| Q4 2020 | $257,000 | +54.8% | 16,620 | -5.1% | 0.00% | – |
| Q3 2020 | $166,000 | +3.1% | 17,505 | -1.8% | 0.00% | -100.0% |
| Q2 2020 | $161,000 | +35.3% | 17,827 | -4.3% | 0.00% | – |
| Q1 2020 | $119,000 | – | 18,634 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |